Effects of antiviral therapy with Telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients

Clinical and Experimental Medicine

Volumn 12, Issue 2, 2012, Pages 105-113

  Shi, T D ^a   Zhang, J M ^b   Wang, X F ^a   Chen, M ^a   Sun, H ^a   Chen, C B ^a   Ren, H ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b Hechuan People's Hospital   (China)

Author keywords

Hepatitis; Hepatitis B virus (HBV); Invariant NKT; PD 1 expression; Telbivudine

Indexed keywords

GAMMA INTERFERON; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 4; PROGRAMMED DEATH 1 RECEPTOR; TELBIVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CHRONICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; INTERFERON PRODUCTION; MALE; MULTICENTER STUDY (TOPIC); NATURAL KILLER T CELL; PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENE EXPRESSION PROFILING; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-GAMMA; MALE; MIDDLE AGED; NATURAL KILLER T-CELLS; NUCLEOSIDES; PROGRAMMED CELL DEATH 1 RECEPTOR; PYRIMIDINONES;

HEPATITIS B VIRUS;

EID: 84861483182     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-011-0151-8     Document Type: Article

References (32)

1. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L (2004) NKT cells: what's in a name? Nat Rev Immunol 4(3):231-237 (Pubitemid 38339089)
2. Van Kaer L (2007) NKT cells: T lymphocytes with innate effector functions. Curr Opin Immunol 19(3):354-364
3. Seino K, Taniguchi M (2005) Functionally distinct NKT cell subsets and subtypes. J Exp Med 202(12):1623-1626 (Pubitemid 41815867)
4. - 8- T cells in mice and humans. J Exp Med 180(3):1097-1106
5. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K et al (1997) CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278(5343):1626-1629 (Pubitemid 27516282)
6. Tillmann HL, McHutchison JG (2007) Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357(25):2576-2588
7. Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM et al (2007) Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 147(11):745-754 (Pubitemid 351664439)
8. Emoto M, Kaufmann SH (2003) Liver NKT cells: an account of heterogeneity. Trends Immunol 24(7):364-369 (Pubitemid 36830962)
9. Klugewitz K, Adams DH, Emoto M, Eulenburg K, Hamann A (2004) The composition of intrahepatic lymphocytes: shaped by selective recruitment? Trends Immunol 25(11):590-594 (Pubitemid 39369735)
10. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV (2000) Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 192(7):921-930
11. de Lalla C, Galli G, Aldrighetti L, Romeo R, Mariani M, Monno A et al (2004) Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J Immunol 173(2):1417-1425 (Pubitemid 38924323)
12. Michel ML, Keller AC, Paget C, Fujio M, Trottein F, Savage PB et al (2007) Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med 204(5):995-1001 (Pubitemid 46798144)
13. Yoshiga Y, Goto D, Segawa S, Ohnishi Y, Matsumoto I, Ito S et al (2008) Invariant NKT cells produce IL-17 through IL-23-dependent and -independent pathways with potential modulation of Th17 response in collagen-induced arthritis. Int J Mol Med 22(3):369-374
14. Nishimura T, Kitamura H, Iwakabe K, Yahata T, Ohta A, Sato M et al (2000) The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int Immunol 12(7):987-994 (Pubitemid 30601366)
15. Moll M, Kuylenstierna C, Gonzalez VD, Andersson SK, Bosnjak L, Sönnerborg A et al (2009) Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection. Eur J Immunol 39(3): 902-911
16. Chen L (2004) Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4(3):336-347
17. Okazaki T, Iwai Y, Honjo T (2002) New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol 14(6):779-782 (Pubitemid 35292426)
18. Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26: 677-704 (Pubitemid 351600389)
19. Parekh VV, Lalani S, Kim S, Halder R, Azuma M, Yagita H et al (2009) PD-1/PD-L Blockade Prevents Anergy Induction and Enhances the Anti-Tumor Activities of Glycolipid-Activated Invariant NKT Cells. J Immunol 182(5):2816-2826
20. Chang WS, Kim JY, Kim YJ, Kim YS, Lee JM, Azuma M et al (2008) Cutting edge: programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J Immunol 181(10):6707-6710
21. Akbari O, Stock P, Singh AK, Lombardi V, Lee WL, Freeman GJ et al (2010) PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell dependent airway hyperreactivity in opposing directions. Mucosal Immunol 3(1):81-91
22. Jung MC, Pape GR (2002) Immunology of hepatitis B infection. Lancet Infect Dis 2(1):43-50
23. Radziewicz H, Hanson HL, Ahmed R, Grakoui A (2008) Unraveling the role of PD-1/PD-L interactions in persistent hepatotropic infections: potential for therapeutic application? Gastroenterology 134(7):2168-2171 (Pubitemid 351783277)
24. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T et al (2007) Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 81(8):4215-4225 (Pubitemid 46586915)
25. Maier H, Isogawa M, Freeman GJ, Chisari FV (2007) PD-1: PD-L1 interactions contribute to the functional suppression of virus-specific CD8? T lymphocytes in the liver. J Immunol 178(5): 2714-2720 (Pubitemid 46333147)
26. Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z (2008) PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 45(4):963-970 (Pubitemid 350019503)
27. Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L (2010) Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138(2):682-693
28. Zhang Z, Zhang JY, Wherry EJ, Jin B, Xu B, Zou ZS et al (2008) Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology 134(7):1938-1949
29. Hashimoto Y, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H et al (2010) Clinical and virological effects of long-term (over 5 years) lamivudine therapy. J Med Virol 82(4):684-691
30. Hann HW (2010) Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses. Expert Opin Pharmacother 11(13):2243-2249
31. Huang YW, Chayama K, Tsuge M, Takahashi S, Hatakeyama T, Abe H et al (2010) Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic. Antivir Ther 15(2):177-184
32. Evans A, Riva A, Cooksley H, Phillips S, Puranik S, Nathwani A et al (2008) Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology 48(3):759-769